Werner Hollriegl
Baxalta Innovations GmbH, Donau City Str. 7
Vienna, 1220, Austria
Vienna, 1220, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Preclinical development of TAK-754, a high-performance AAV8-based vector expressing coagulation factor VIII.
Journal: Molecular therapy. Methods & clinical development
Published: August 30, 2024
Treatment with recombinant ADAMTS13, alleviates hypoxia/reoxygenation-induced pathologies in a mouse model of human sickle cell disease.
Journal: Journal of thrombosis and haemostasis : JTH
Published: May 10, 2022
Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease.
Journal: Haematologica
Published: October 26, 2021
Absence of exaggerated pharmacology by recombinant ADAMTS13 in the rat and monkey.
Journal: Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
Published: July 16, 2021
Minimal Essential Human Factor VIII Alterations Enhance Secretion and Gene Therapy Efficiency.
Journal: Molecular therapy. Methods & clinical development
Published: August 18, 2020
Development of an In Vitro Biopotency Assay for an AAV8 Hemophilia B Gene Therapy Vector Suitable for Clinical Product Release.
Journal: Molecular therapy. Methods & clinical development
Published: February 19, 2020
Evaluation of Factor VIII Polysialylation: Identification of a Longer-Acting Experimental Therapy in Mice and Monkeys.
Journal: The Journal of pharmacology and experimental therapeutics
Published: May 21, 2019
Detection of Biologically Relevant Low-Titer Neutralizing Antibodies Against Adeno-Associated Virus Require Sensitive In Vitro Assays.
Journal: Human gene therapy methods
Published: February 09, 2019
Coagulation phenotype of wild-type mice on different genetic backgrounds.
Journal: Laboratory animals
Published: November 14, 2018
Pharmacokinetics, disease-modifying activity, and safety of an experimental therapeutic targeting an immunological isoform of macrophage migration inhibitory factor, in rat glomerulonephritis.
Journal: European journal of pharmacology
Published: October 17, 2017
Preclinical assessment of a new recombinant ADAMTS-13 drug product (BAX930) for the treatment of thrombotic thrombocytopenic purpura.
Journal: Journal of thrombosis and haemostasis : JTH
Published: December 23, 2015
Porcine recombinant factor VIII (Obizur; OBI-1; BAX801): product characteristics and preclinical profile.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: July 03, 2015
Last Updated: 09/26/2026